What is Nuclera?
Founded in 2013 by University of Cambridge researchers, Nuclera specializes in eProtein desktop bioprinting technology. The company addresses a fundamental bottleneck in biological research: the inaccessibility and slow turnaround times associated with protein supply. By enabling researchers to produce proteins on-demand, Nuclera effectively shifts the paradigm of laboratory efficiency. Its market position is defined by its ability to integrate hardware, software, and wetware into a cohesive platform that empowers scientists to accelerate their experimental cycles, thereby reducing the time-to-market for therapeutic innovations.
How much funding has Nuclera raised?
Nuclera has raised a total of $157.6M across 5 funding rounds:
Series A
$11.2M
Series B
$58M
Grant
$1.4M
Series C
$75M
Series C
$12M
Series A (2018): $11.2M with participation from RT Partners
Series B (2022): $58M led by Amadeus Capital Partners, Jonathan Milner, Verve Ventures, Future Planet Capital, M&G, RT Partners, and E Ink
Grant (2024): $1.4M supported by UK Research & Innovation
Series C (2024): $75M featuring British Patient Capital, Elevage Medical Technologies, Patient Square Capital, and Cambridge Innovation Capital
Series C (2026): $12M backed by G K Goh Holdings, British Business Bank, and Elevage Medical Technologies
Key Investors in Nuclera
Patient Square Capital
A specialized investment firm focused exclusively on the healthcare industry, providing strategic capital to companies that aim to improve patient outcomes and advance medical innovation.
Cambridge Innovation Capital
A venture investor with deep ties to the University of Cambridge, specializing in backing high-potential entrepreneurs within the life sciences and deep tech ecosystems.
Elevage Medical Technologies
An investment firm dedicated to supporting medical technology companies through capital and operational support to improve health outcomes and quality of life.
What's next for Nuclera?
With this latest round of financing, Nuclera is poised to scale its manufacturing capabilities and expand its commercial footprint across global research markets. The strategic focus will likely center on enhancing the throughput of its eProtein systems and deepening its integration within the pharmaceutical R&D ecosystem. As the company transitions from a high-growth venture to an established industry player, the focus will shift toward operational excellence and the widespread adoption of its proprietary bioprinting technology, ensuring that the next generation of biological discovery is both faster and more accessible.
See full Nuclera company page
